Faruqi and Faruqui, LLP Logo
Share this page

Puma Biotechnology, Inc. (PBYI)

(NYSE: PBYI)

Summary

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Puma Biotechnology, Inc. (PBYI) To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Puma Biotechnology, Inc. (“Puma” or the “Company”) (NYSE: PBYI).

The investigation focuses on whether the Company and its executives violated federal securities laws by issuance of certain statements regarding a New Drug Application (“NDA”) submission.

On December 2, 2014, Puma announced that an NDA would be filed for neratinib (PB272), a breast cancer drug candidate, in the first quarter of 2016 rather than the first half of 2015 as previously stated. 

Following news of the delay in filing, Puma shares declined by $27.33 per share, more than 12%, closing on December 3, 2014 at $197.67 per share. 

Take Action

If you invested in Puma stock or options through December 2, 2014 and would like to discuss your legal rights, you can contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.  Faruqi & Faruqi, LLP also encourages anyone with information regarding Puma’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Contact Counsel

Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330

Email:

Case Details

Date:

  • 02/09/2015

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.